About Genmab A/SGenmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications and DARZALEX™ (daratumumab) for the treatment of heavily pretreated or double refractory multiple myeloma. Daratumumab is in clinical development for additional multiple myeloma indications and for non-Hodgkin’s lymphoma. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies.
CEO and Founder: Jan G. J. van de Winkel, Ph.D.
CFO: David Eatwell
JOBS: Please click here for Genmab job opportunities.
Please click here for clinical trial information.
FOLLOW GENMAB: Tweets by Genmab
365 articles with Genmab A/S
In a brief statement, Genmab said it initiated binding arbitration related to two matters under its Darzalex (daratumumab) license agreement with Janssen Biotech.
Seattle Genetics and Genmab Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020
Seattle Genetics and Genmab Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020 - Data Featured in Late-Breaking Proffered Paper Oral Presentation - - Biologics License Application Submission Planned to Support Accelerated Approval Pathway with the FDA - BOTHELL, Wash. & COPENHAGEN, Denmark--( BUSINESS WIRE )-- Seattle Genetics, Inc. (Nasdaq:SGEN) an
AbbVie and Genmab entered into a broad collaboration to jointly develop and commercialize three of Genmab's next-generation bispecific antibody products, including epcoritamab
The collaboration will focus on the development of three of Genmab's bispecific antibodies and will also involve a discovery research collaboration for future antibody therapeutics for cancer.
Tavotek Announces a Research Agreement with Genmab for the Development of Bispecific Antibodies using Genmab's DuoBody® Platform against a Pair of Disease Relevant Targets
Tavotek Biotherapeutics, a biotech company which develops novel biologics for autoimmune diseases and oncology, announced that it has entered into a research agreement with Genmab A/S of Denmark to create and develop bispecific antibodies using Genmab's DuoBody® technology platform against disease relevant target antigens.
Here’s a look at some of the biggest U.S. Nasdaq-based initial public offerings in 2019 and some of the more intriguing ones.
Genmab A/S (Nasdaq: GMAB) and CureVac AG announced today that Genmab and CureVac have entered into a research collaboration and license agreement.
Completion of public offering and listing of American Depository Shares (ADSs) on Nasdaq Global Select Market under the symbol “GMAB.” Total gross proceeds from the issuance of new shares amounted to USD 582 million (DKK 3,873 million) with a corresponding increase in share capital of 3,277,500 ordinary shares or 32,775,000 ADSs
9/3/2019Rounding out the traditional summer months, last week had plenty of clinical trial news. Here’s a look at some of the top stories.
The trials met the primary endpoints, with ofatumumab demonstrating a highly significant and clinically meaningful decrease in the number of confirmed relapses. The trials also hit key secondary endpoints, delaying the time to confirmed disability progression.
7/18/2019Genmab A/S, located in Copenhagen, Denmark, raised $506 million with its initial public offering (IPO). The company trades on the Nasdaq under the ticker symbol GMAB.
Genedata E2E software solution to increase speed and efficiency of discovery and development of Genmab’s next-generation cancer therapies
Darzalex in combination with lenalidomide and dexamethasone was approved as a first-line treatment for multiple myeloma patients who are ineligible for autologous stem cell transplant.
The agreement is the outcome of preclinical research on novel CD38 targeting concepts conducted by Genmab.
The company’s board of directors hasn’t made a final decision to proceed with the listing.
Darzalex (daratumumab) for intravenous infusion is approved in the U.S. in combination with bortezomib, melphalan and prednisone for patients with newly diagnosed multiple myeloma (MM) who are ineligible for autologous stem cell transplant.
MorphoSys AG announced today that in its lawsuit against Janssen Biotech and Genmab A/S, the parties have settled the dispute.
Ad hoc: MorphoSys Announces That Its Patents Were Ruled Invalid in Patent Lawsuit Against Janssen and Genmab
MorphoSys AG announces that it was informed that in its lawsuit against Janssen Biotech and Genmab A/S, the United States (U.S.) District Court of Delaware has ruled in a Court Order on January 25, 2019, that the asserted claims of three MorphoSys patents with U.S. Patent Numbers 8,263,746, 9,200,061 and 9,758,590 are invalid.
The American Society of Hematology is holding its 60th Annual Meeting & Exposition starting December 1 and running through December 4 in San Diego. Most of the players, big and small, in cancer drug therapies will be there, presenting updates and breaking stories about their hematology pipelines.
Denmark-based Genmab A/S released topline data from its Phase III MAIA trial of a drug it licensed to Johnson & Johnson’s Janssen Biotech, Darzalex (daratumumab).